ACTU
HEALTHCAREActuate Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving ACTU Today?
No stock-specific AI insight has been generated for ACTU yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.99
Fundamentals
Trading
ACTU News
20 articles- Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of DirectorsYahoo Finance·May 6, 2026
- Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaYahoo Finance·Apr 14, 2026
- Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven CancersYahoo Finance·Mar 24, 2026
- Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS InhibitorsYahoo Finance·Mar 9, 2026
- Actuate Therapeutics to Present at The Citizens Life Sciences ConferenceYahoo Finance·Mar 4, 2026
- Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 24, 2026
- Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the bruntYahoo Finance·Feb 4, 2026
- Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory CancersYahoo Finance·Jan 21, 2026
- Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026Yahoo Finance·Jan 12, 2026
- Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 DataYahoo Finance·Jan 6, 2026
- Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric CancersYahoo Finance·Jan 6, 2026
- Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Dec 24, 2025
- Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026Yahoo Finance·Dec 18, 2025
- Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland CarcinomaYahoo Finance·Dec 15, 2025
- How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%Yahoo Finance·Nov 28, 2025
- Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn SituationYahoo Finance·Nov 15, 2025
- Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming MonthsYahoo Finance·Sep 22, 2025
- Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment OptionYahoo Finance·Sep 11, 2025
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Sep 10, 2025
- Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common StockYahoo Finance·Sep 10, 2025
All 20 articles loaded
Price Data
52-Week Range
$2.99
Fundamentals
Trading
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for patients with serious diseases, particularly in the oncology sector. The company is progressing its proprietary drug candidates through comprehensive clinical trials to address significant unmet medical needs, thereby enhancing patient outcomes. With a commitment to innovative therapeutic approaches, Actuate is cultivating a strong pipeline that not only aims for strategic growth but also seeks to deliver substantial value to investors, solidifying its position in the biotechnology industry.